Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Risk-Based Triaged Mammograms Demonstrate Success During Periods of Reduced Capacity

April 28th 2021

Triaging individuals with the highest likelihood of cancer detection with their clinical indication and individual risk factors during periods of reduced capacity could be an efficient way of identifying the most cancers with the least examinations compared with a non–risk-based approach.

Dr. Gogineni on the Efficacy of CDK4/6 Inhibitors Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer

April 27th 2021

Keerthi Gogineni, MD, MSHP, discusses the efficacy of CDK4/6 inhibitors plus endocrine therapy in patients with hormone receptor–positive, HER2-negative early breast cancer.

FDA Panel Supports Atezolizumab/Nab-Paclitaxel Combo for PD-L1+ Metastatic TNBC

April 27th 2021

The FDA's Oncologic Drugs Advisory Committee voted 7 to 2 in support of maintaining the indication of atezolizumab in combination with nab-paclitaxel as a treatment for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors are PD-L1 positive.

Bringing Individualized Care to Patients With Breast and Ovarian Cancers in the Caribbean

April 26th 2021

Current breast cancer screening practices in the Caribbean exclude the majority of the younger patient population, thereby leaving many cases of breast cancer undiagnosed.

ODAC Hearings on 6 Immunotherapy Indications Set to Begin

April 26th 2021

The FDA’s Oncologic Drugs Advisory Committee is poised to move forward this week with a public review of 6 indications for immune checkpoint inhibitors granted under the agency’s accelerated approval process that later failed to reach thresholds for statistical significance for key end points in confirmatory clinical trials.

Gradishar Highlights Cetirizine as Management Tool for Hypersensitivity Infusion Reactions in Breast Cancer and Beyond

April 23rd 2021

William Gradishar, MD, discusses the phase 2 data evaluating the activity with IV cetirizine and its potential use in patients with breast cancer.

Dr. Hahn on Future Research Directions with Tucatinib in Breast Cancer

April 23rd 2021

Olwen Hahn, MD, discusses future research directions with tucatinib (Tukysa) in the treatment of patients with breast cancer.

A Desire to Be a Healer Drives Breast Cancer Expert Forward

April 23rd 2021

Sara A. Hurvitz, MD, can remember the exact moment she decided to become an oncologist. It was her first day at the University of Southern California School of Medicine, which she had entered in 1995 without a firm idea of what discipline she wanted to pursue.

Dr. Gradishar on Pretreating for Infusion Reactions in Breast Cancer and Other Malignancies

April 22nd 2021

William Gradishar, MD, discusses the importance of pretreatment to prevent drug-induced infusion reactions in patients with breast cancer and other malignancies.

Dr. Meisel on Sequencing Therapies in Metastatic HER2+ Breast Cancer

April 21st 2021

Jane L. Meisel, MD, discusses sequencing therapies for patients with metastatic HER2-positive breast cancer.

NICE Recommends Trastuzumab Deruxtecan in Advanced HER2+ Breast Cancer

April 20th 2021

The National Institute for Health and Care Excellence has published draft guidance that recommends fam-trastuzumab deruxtecan-nxki for the treatment of patients with unresectable or metastatic HER2-positive breast cancer following 2 or more anti-HER2 therapies.

Dr. Gradishar on Pretreatment With Cetirizine to Prevent Infusion Reactions in Breast Cancer and Other Malignancies

April 19th 2021

William Gradishar, MD, discusses the efficacy of pretreatment with intravenous cetirizine in the prevention of infusion reactions in patients with breast cancer and other malignancies.

Dr. Bhave on Promising Combination Strategies in TNBC

April 16th 2021

Manali Bhave, MD, discusses promising combination strategies in triple-negative breast cancer.

NK Cell–Targeting Strategies Come Into Their Own

April 16th 2021

Although anticancer therapies that leverage T cells have commanded the most attention in the immuno-oncology era of the past decade, strategies based on natural killer cells have recently emerged as attractive approaches.

Addition of SDX-7320 to Palbociclib Inhibits Tumor Growth in Breast Cancer Xenografts

April 15th 2021

The addition of SDX-7320, a novel inhibitor of methionine aminopeptidase 2, to palbociclib was found to inhibit MCF-7 tumor growth and reduce the expression of proteins associated with resistance to palbociclib.

Overall Survival After Surgery for Spinal Metastases Has Improved Over the Past Two Decades

April 15th 2021

Postoperative survival after surgery for spinal metastases has improved over the past 20 years, particularly in patients with kidney, breast, lung, and colon tumors metastatic to the spine.

Triplet Combos Targeting ER, CDK4/6, and PIK3CA Inhibit Tumor Growth in ER+ Breast Cancer

April 14th 2021

A triplet combination regimen that targets PIK3CA mutations, ER, and CDK4/6 can reduce and inhibit tumor growth in preclinical models of estrogen receptor–positive breast cancer that is resistant to fulvestrant plus a CDK4/6 inhibitor or PI3K inhibitor.

Unanswered Questions in HER2+ Breast Cancer

April 14th 2021

Considerations on the evolving landscape and ongoing unmet needs for patients with HER2+ breast cancer.

Approaches to Sequencing for Metastatic HER2+ BC

April 14th 2021

Volkmar Mueller, MD, shares insight on the potential sequencing of available therapeutics for patients with metastatic HER2+ breast cancer.

cfDNA, Genetic Assays Inform Important Treatment Decisions in Breast Cancer

April 14th 2021

Genetic assays such as those utilized in the phase 3 TAILORx, MINDACT, and RxPONDER trials are helping to provide valuable insight to inform treatment decisions in patients with breast cancer.